8-K: UroGen Pharma Reports Double-Digit JELMYTO Growth and Advances UGN-102 Submission

UroGen Pharma announced strong JELMYTO revenue growth, progress on UGN-102 regulatory submission, and a restructured financing agreement.

Summary

• UroGen Pharma reported its financial results for the fourth quarter and full year of 2023, highlighting a 28% increase in JELMYTO net product revenue to $82.7 million for the year.
• The company initiated a rolling New Drug Application (NDA) submission to the FDA for UGN-102, with completion expected in September 2024 and a potential FDA decision as early as the first quarter of 2025.
• UroGen also announced a licensing agreement with medac GmbH for next-generation mitomycin-based formulations, potentially extending patent protection until December 2041.
• A restructured agreement with Pharmakon Advisors provides up to an additional $100 million credit facility, with an initial $25 million draw required by September 30, 2024.
• The company anticipates full-year 2024 JELMYTO net product revenues to be between $95 and $102 million and operating expenses between $175 and $185 million.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue growth for JELMYTO and progress on UGN-102. However, the company is still operating at a loss and has high operating expenses, which tempers the overall sentiment.

Positives

• JELMYTO sales grew by 28% year-over-year, indicating strong market adoption.
• The initiation of the NDA submission for UGN-102 is a significant step towards potential approval.
• The licensing agreement with medac GmbH provides a pathway for future product development and patent protection.
• The restructured loan agreement with Pharmakon Advisors provides additional financial flexibility.
• The company's cash position is strong at $141.5 million as of December 31, 2023.

Negatives

• Full-year 2023 JELMYTO net revenues were impacted by higher than forecast 340B chargebacks and first time estimated Medicare refunds for discarded drug.
• The company reported a net loss of $102.2 million for the full year 2023.
• Operating expenses are expected to be high in 2024, between $175 and $185 million.

Risks

• The success of UGN-102 is dependent on positive results from the ENVISION trial and FDA approval.
• The company's financial performance is subject to market conditions and competition.
• There are risks associated with the development and commercialization of new products.
• The company's ability to access the additional $75 million under the amended credit facility is subject to certain drawdown conditions.
• Increased discounts related to Medicare refunds for discarded drugs and 340B purchases will further impact net revenues in 2024.

Future Outlook

UroGen anticipates continued growth in JELMYTO sales and is focused on completing the NDA submission for UGN-102, with a potential FDA decision in early 2025. The company also plans to initiate Phase 3 studies for UGN-103 and UGN-104 in 2024.

Management Comments

• Liz Barrett, President and CEO, stated that 2023 was a year of important operational and clinical milestones, setting the company up for further success.
• Liz Barrett highlighted the potential of UGN-102 to fundamentally change the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer.
• Management expects JELMYTO patient and physician adoption to continue to increase.

Industry Context

The announcement highlights UroGen's progress in the urothelial cancer treatment space, where there is a need for less invasive treatment options. The company's focus on non-surgical treatments aligns with a broader trend in oncology towards more patient-friendly therapies.

Comparison to Industry Standards

• UroGen's 28% year-over-year growth in JELMYTO revenue is strong compared to the average growth rate of pharmaceutical companies in the oncology space.
• The initiation of the NDA submission for UGN-102 is a significant milestone, putting UroGen in a competitive position with other companies developing treatments for non-muscle invasive bladder cancer.
• The licensing agreement with medac GmbH for next-generation mitomycin-based formulations is a strategic move to extend patent protection and maintain a competitive edge.
• Companies like Photocure and CG Oncology are also developing treatments for bladder cancer, making the market competitive.

Stakeholder Impact

• Shareholders will be encouraged by the revenue growth and progress on UGN-102.
• Patients will benefit from the development of new treatment options for urothelial cancer.
• Employees will be impacted by the company's financial performance and growth prospects.
• Creditors will be impacted by the company's debt obligations and financial stability.

Next Steps

• UroGen will complete the NDA submission for UGN-102 in September 2024.
• The company will report 12-month duration of response data from the ENVISION trial in the second quarter of 2024.
• UroGen plans to initiate Phase 3 studies for UGN-103 and UGN-104 in 2024.
• The company will draw down $25 million from the Pharmakon Advisors credit facility by September 30, 2024.

Key Dates

Keywords

JELMYTO, UGN-102, mitomycin, urothelial cancer, FDA, NDA, RTGel, Pharmakon Advisors, medac GmbH, LG-IR-NMIBC, LG-UTUC